However, Ozempic (another form of semaglutide) and Mounjaro (tirzepatide) are only FDA approved for type 2 diabetes, not weight loss
Ive personally never experienced significant adverse effects from DSIP, and in my decades of working with therapeutic peptides, it stands out as a benign compound in terms of safety profile
Cognitive function improvement with astaxanthin and tocotrienol intake: A randomized, double-blind, placebo-controlled study
Medi-Cal will continue to cover GLP-1s when used for FDA-approved, non-weight-loss indications (e.g., type 2 diabetes, ASCVD, CKD) with appropriate ICD-10 codes and, when required, prior authorization
This is when iron deficiency anemia is most readily recognized in the laboratory
Medications like Ozempic can also lead to unintended facial volume loss, often referred to as "Ozempic face." While effective in reducing body fat, it doesnt target specific areas, meaning you lose fat from your body and face